Bharat Biotech is collaborating with virologists at the University of Wisconsin–Madison and the vaccine company, FluGen, for the project.
Bharat Biotech, the country’s pandemic vaccine leader, is working on an intranasal vaccine against coronavirus disease (Covid-19) called “CoroFlu”.
Bharat Biotech is collaborating with virologists at the University of Wisconsin–Madison and the vaccine company, FluGen, for the project.
CoroFlu is in the animal testing phase in the US, and is expected to move to human trials in the next three months.
“Bharat Biotech will manufacture the vaccine, conduct clinical trials, and prepare to produce almost 300 million doses of vaccine for global distribution. Under the collaboration agreement, FluGen will transfer its existing manufacturing processes to Bharat Biotech to enable the company to scale up production and produce the vaccine for clinical trials,” said Raches Ella, head, business development, Bharat Biotech.
More
DelMarVa's Premier Source for News, Opinion, Analysis, and Human Interest Contact Publisher Joe Albero at alberobutzo@wmconnect.com or 410-430-5349
True fact, as they have quietly said we are going to be in this "Shelter at Home" thing thru summer.
ReplyDeleteRemember when elected officials committed insider trading and no one cared?
ReplyDeleteLooks like FDA and Big Pharma is in control again. They see no National emergency just another way to make millions. Trump needs to eliminate the 10 year moratorium on new drugs and allow generic as soon as possible.
ReplyDelete